- Vienna '18
- Athens 2019
- ESCRS Player
- On Demand
- ESCRS iLearn
- ESCRS YO's
Session Title: IOL Technology
Session Date/Time: Sunday 06/10/2013 | 16:30-18:30
Paper Time: 17:23
Venue: Auditorium (First Floor)
First Author: : F.Kretz GERMANY
Co Author(s): : A. Fitting R. Khoramnia T. Rabsilber M. Holzer G. Auffarth
Clinical evaluation of functional results and quality of vision after implantation of an aspheric, aberration neutral, monofocal intraocular lens (IOL).
International Vision Correction Research Centre (IVCRC), Department of Ophthalmology, University of Heidelberg, Heidelberg, Germany
18 eyes of 12 patients (median age: 70 years) with cataract have been enrolled in this ongoing prospective clinical study so far that was approved by the ethics committee. The Tecnis 1-Piece aspheric IOL (AMO, USA) was implanted after phacoemulsification. Follow-up examinations were performed two to four months after surgery including subjective refraction, ETDRS uncorrected (UDVA) and corrected distance visual acuity (CDVA), wavefront analysis, analysis of stray light (C-Quant), contrast sensitivity under different lighting conditions (F.A.C.T.) and a questionnaire.
Two to four months after surgery, median UDVA was 0.17 logMAR (range: -0.26 to 0.88 logMAR). Median CDVA increased from 0.20 logMAR (range: -0.02 to 0.80 logMAR) preoperatively to -0.10 logMAR (range: -0.30 to 0.10 logMAR) postoperatively. Median difference between achieved vs. intended spherical equivalent was +0.11 D (range: -0.30 to +1.03 D). Median total HOA RMS (6 mm pupil size) was 1.73 µm (range: 0.56 to 3.93 µm). The median spherical aberrations were -0.07 µm (range: -0.37 to 0.07 µm). Analysis of stray light (C-Quant) revealed a median value of 1.28 log(s) (range: 0.89 to 1.52 log(s)).
The Tecnis 1-Piece aspheric IOL provides good and predictable functional results after surgery. Patients are mostly not negatively influenced by stray light and show slightly negative spherical aberrations.
... receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, ... travel has been funded, fully or partially, by a competing company, ... travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, ... research is funded, fully or partially, by a competing company, ... research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, ... receives consulting fees, retainer, or contract payments from a competing company
Please wait while information is loading.